aclarubicin
Small moleculeexperimental
Aclarubicin (INN) or aclacinomycin A is an anthracycline drug that is used in the treatment of cancer in China. It was previously approved for use in Europe but was discontinued in 2004 due to being rarely prescribed and unprofitable. — Wikipedia
Clinical trial activity
20 trials · 30 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
13
Phase 3
7
Phase 4
1
Earliest trial started Nov 1, 2012 (NCT01690507)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- DNA topoisomerase IINHIBITOR
TOP1 inhibitor
- DNA topoisomerase II alphaINHIBITOR
TOP2A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC- Mol. weight
- 811.88 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAclarubicin ↗
- ChEMBLCHEMBL502620 ↗
Also known as
- aclacinomycin
- aclacinomycin a
- aclacinomycin a
- aclacinomycin a
- aclacinomycin a
- aclacinomycin hydrochloride
- aclacinomycin s
- aclacinomycin t
- aclacinomycin x
- aclacinomycin y
- aclarubicin
- aclarubicin
- aclarubicin
- aclarubicin
- aclarubicin
- aclarubicin
- aclarubicin hcl
- aclarubicin hcl
- aclarubicin hcl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06394011 | Phase 2 | Feb 15, 2024 | Soochow University |
| NCT05805072 | N/A | May 1, 2023 | Soochow University |
| NCT05918198 | Phase 2 | Feb 1, 2023 | Peking University |
| NCT05726110 | Phase 3 | Jan 29, 2023 | Antengene Corporation, Shanxi Bethune Hospital |
| NCT05662956 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2022 | People's Liberation Army of China |
| NCT05659992 | Phase 1 | Jan 10, 2022 | People's Liberation Army of China |
| NCT05264883 | Phase 3 | Mar 1, 2021 | Huai'an First People's Hospital, Nanjing Medical University, Nanjing University, Yancheng First People's Hospital |
| NCT04254640 | Phase 2 | Jun 1, 2020 | Sun Yat-Sen University |
| NCT04216355 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2020 | Fujian Medical University |
| NCT04087967 | Phase 3 | Apr 1, 2019 | Changzhou No.2 People's Hospital, Huai'an Second People's Hospital, Jingjiang People's Hospital, Kunming Medical University, Soochow University, The First People's Hospital of Lianyungang, Zhangjiagang First People's Hospital |
| NCT04083911 | Phase 3 | Apr 1, 2019 | Changzhou No.2 People's Hospital, Jingjiang People's Hospital, Kunming Medical University, Soochow University, The First People's Hospital of Lianyungang, The Second People's Hospital of Huai'an, Zhangjiagang First People's Hospital |
| NCT04446130 | Phase 3 | Jan 1, 2019 | Anhui Medical University, Changzhou No.2 People's Hospital, Henan Medical University, Nanjing University, Shandong Provincial Hospital, Shenzhen University, Soochow University, The Second People's Hospital of Huai'an |
| NCT03045627 | Phase 2 | Jan 1, 2017 | Shandong University |
| NCT03181815 | Phase 2 | Jan 1, 2017 | Sun Yat-Sen University |
| NCT03026842 | Phase 4 | Jan 1, 2017 | Dalian Medical University, Jilin University |
| NCT02723448 | Phase 1 | Dec 1, 2016 | Washington University in St. Louis |
| NCT02850822 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2016 | Guangzhou Medical University, Southern Medical University, Sun Yat-Sen University |
| NCT02886559 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2016 | Government of China, People's Liberation Army of China |
| NCT02432911 | N/A | Apr 1, 2015 | Chinese Academy of Medical Sciences |
| NCT01690507 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2012 | Government of China, People's Liberation Army of China |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (30)
30 organizations
Page 1 / 2